Compare ARCO & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCO | ATAI |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | Uruguay | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2011 | 2025 |
| Metric | ARCO | ATAI |
|---|---|---|
| Price | $8.52 | $4.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $8.60 | ★ $15.88 |
| AVG Volume (30 Days) | 1.3M | ★ 5.0M |
| Earning Date | 05-20-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,089,000.00 |
| Revenue This Year | $12.56 | N/A |
| Revenue Next Year | $3.48 | N/A |
| P/E Ratio | $7.26 | ★ N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $6.51 | $2.00 |
| 52 Week High | $9.75 | $6.73 |
| Indicator | ARCO | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 48.41 | 48.20 |
| Support Level | $8.51 | $4.00 |
| Resistance Level | $8.98 | $4.20 |
| Average True Range (ATR) | 0.26 | 0.33 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 48.00 | 29.20 |
Arcos Dorados Holdings Inc operates McDonald's branded restaurants in various countries and territories in Latin America and the Caribbean. The Company manages its business as distinct geographic segments and its operations are divided into three geographic divisions, as follows: Brazil, the North Latin American division, or NOLAD, which is comprised of Costa Rica, Mexico, Panama, Puerto Rico, Martinique, Guadeloupe, French Guiana and the U.S. Virgin Islands of St. Croix and St. Thomas and the South Latin American division, or SLAD, which is comprised of Argentina, Chile, Ecuador, Peru, Uruguay, Colombia, Venezuela, Trinidad and Tobago, Aruba and Curacao. Their menu includes hamburgers, McNuggets, salad, sandwiches, French fries, and others.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.